Last reviewed · How we verify
PRF is added in the test group.
PRF (Platelet-Rich Fibrin) is a biomaterial derived from patient blood that concentrates platelets and growth factors to promote tissue regeneration and healing.
PRF (Platelet-Rich Fibrin) is a biomaterial derived from patient blood that concentrates platelets and growth factors to promote tissue regeneration and healing. Used for Bone and soft tissue regeneration in dental and oral surgery, Wound healing and tissue repair, Orthopedic and maxillofacial applications.
At a glance
| Generic name | PRF is added in the test group. |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | Regenerative medicine / Biomaterial |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Wound Healing / Dentistry / Orthopedics |
| Phase | FDA-approved |
Mechanism of action
PRF is prepared by centrifuging whole blood to separate and concentrate platelets, leukocytes, and fibrin into a matrix. When applied to tissue defects, it releases growth factors (PDGF, VEGF, TGF-β) and cytokines that stimulate angiogenesis, collagen deposition, and cellular proliferation, accelerating wound healing and tissue repair.
Approved indications
- Bone and soft tissue regeneration in dental and oral surgery
- Wound healing and tissue repair
- Orthopedic and maxillofacial applications
Common side effects
- Infection at application site
- Inflammation
- Allergic reaction
Key clinical trials
- Clinical and Radiographic Assessment of Platelet Rich Fibrin and Mineral Trioxide Aggregate as Pulp Capping Biomaterials (NA)
- Ultrasonographic Assessment of Palatal Wound Healing
- The Use of Platelet-rich Fibrin (PRF) Membranes in Lateral Alveolar Ridge Augmentation When Jaw Bone is Missing Before Dental Implant Installation. A Study Comparing an Autogenous Bone Block Graft Covered Either by a (PRF) Membrane (Test) or Bone Substitute and a Barrier Membrane (Control) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |